Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Identifieur interne : 003851 ( PubMed/Curation ); précédent : 003850; suivant : 003852Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Auteurs : Juan W. Valle [Suède] ; Daniel Palmer ; Richard Jackson ; Trevor Cox ; John P. Neoptolemos ; Paula Ghaneh ; Charlotte L. Rawcliffe ; Claudio Bassi ; Deborah D. Stocken ; David Cunningham ; Derek O'Reilly ; David Goldstein ; Bridget A. Robinson ; Christos Karapetis ; Andrew Scarfe ; Francois Lacaine ; Juhani Sand ; Jakob R. Izbicki ; Julia Mayerle ; Christos Dervenis ; Attila Oláh ; Giovanni Butturini ; Pehr A. Lind ; Mark R. Middleton ; Alan Anthoney ; Kate Sumpter ; Ross Carter ; Markus W. BüchlerSource :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Adénocarcinome (), Adénocarcinome (traitement médicamenteux), Analyse de survie, Antinéoplasiques antimétabolites (administration et posologie), Calendrier d'administration des médicaments, Carcinome du canal pancréatique (), Carcinome du canal pancréatique (traitement médicamenteux), Désoxycytidine (administration et posologie), Désoxycytidine (analogues et dérivés), Femelle, Fluorouracil (administration et posologie), Humains, Mâle, Sujet âgé, Survie sans rechute, Taux de survie, Traitement médicamenteux adjuvant (), Tumeurs du pancréas (), Tumeurs du pancréas (traitement médicamenteux).
- MESH :
- administration et posologie : Antinéoplasiques antimétabolites, Désoxycytidine, Fluorouracil.
- analogues et dérivés : Désoxycytidine.
- traitement médicamenteux : Adénocarcinome, Carcinome du canal pancréatique, Tumeurs du pancréas.
- Adulte d'âge moyen, Adénocarcinome, Analyse de survie, Calendrier d'administration des médicaments, Carcinome du canal pancréatique, Femelle, Humains, Mâle, Sujet âgé, Survie sans rechute, Taux de survie, Traitement médicamenteux adjuvant, Tumeurs du pancréas.
English descriptors
- KwdEn :
- Adenocarcinoma (drug therapy), Adenocarcinoma (surgery), Aged, Antimetabolites, Antineoplastic (administration & dosage), Carcinoma, Pancreatic Ductal (drug therapy), Carcinoma, Pancreatic Ductal (surgery), Chemotherapy, Adjuvant (methods), Deoxycytidine (administration & dosage), Deoxycytidine (analogs & derivatives), Disease-Free Survival, Drug Administration Schedule, Female, Fluorouracil (administration & dosage), Humans, Male, Middle Aged, Pancreatic Neoplasms (drug therapy), Pancreatic Neoplasms (surgery), Survival Analysis, Survival Rate.
- MESH :
- chemical , administration & dosage : Antimetabolites, Antineoplastic, Deoxycytidine, Fluorouracil.
- chemical , analogs & derivatives : Deoxycytidine.
- drug therapy : Adenocarcinoma, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms.
- methods : Chemotherapy, Adjuvant.
- surgery : Adenocarcinoma, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms.
- Aged, Disease-Free Survival, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Survival Analysis, Survival Rate.
Abstract
Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown.
DOI: 10.1200/JCO.2013.50.7657
PubMed: 24419109
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003966
Links to Exploration step
pubmed:24419109Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.</title><author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name><affiliation wicri:level="1"><nlm:affiliation>Juan W. Valle, Derek O'Reilly, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester; Richard Jackson, Trevor Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte L. Rawcliffe, Liverpool Cancer Research UK Centre and the National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, Liverpool; Daniel Palmer, the Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust; Deborah D. Stocken, the Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; David Cunningham, Royal Marsden Hospital Foundation Trust, Sutton; Mark R. Middleton, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford; Alan Anthoney, The Leeds Teaching Hospital Trust, Leeds; Kate Sumpter, Freeman Hospital, Newcastle upon Tyne; Ross Carter, Glasgow Royal Infirmary, Glasgow, United Kingdom; Claudio Bassi, Giovanni Butturini, University of Verona, Verona, Italy; David Goldstein, Bridget A. Robinson, Christos Karapetis, the Australasian Gastro-Intestinal Trials Group, Camperdown, Australia; Andrew Scarfe, University of Alberta, Edmonton, Canada; Francois Lacaine, Hôpital TENON, Assistance Publique Hôpitaux de Paris, Universite Pierre Et Marie Curie, Paris, France; Juhani Sand, Tampere University Hospital, Tampere, Finland; Jakob R. Izbicki, University of Hamburg, Hamburg; Julia Mayerle, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald; Markus W. Büchler, University of Heidelberg, Heidelberg, Germany; Christos Dervenis, the Agia Olga Hospital, Athens, Greece; Attila Oláh, the Petz Aladar Hospital, Gyor, Hungary; Pehr A. Lind, Karolinska-Stockholm Söder Hospital, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Juan W. Valle, Derek O'Reilly, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester; Richard Jackson, Trevor Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte L. Rawcliffe, Liverpool Cancer Research UK Centre and the National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, Liverpool; Daniel Palmer, the Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust; Deborah D. Stocken, the Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; David Cunningham, Royal Marsden Hospital Foundation Trust, Sutton; Mark R. Middleton, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford; Alan Anthoney, The Leeds Teaching Hospital Trust, Leeds; Kate Sumpter, Freeman Hospital, Newcastle upon Tyne; Ross Carter, Glasgow Royal Infirmary, Glasgow, United Kingdom; Claudio Bassi, Giovanni Butturini, University of Verona, Verona, Italy; David Goldstein, Bridget A. Robinson, Christos Karapetis, the Australasian Gastro-Intestinal Trials Group, Camperdown, Australia; Andrew Scarfe, University of Alberta, Edmonton, Canada; Francois Lacaine, Hôpital TENON, Assistance Publique Hôpitaux de Paris, Universite Pierre Et Marie Curie, Paris, France; Juhani Sand, Tampere University Hospital, Tampere, Finland; Jakob R. Izbicki, University of Hamburg, Hamburg; Julia Mayerle, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald; Markus W. Büchler, University of Heidelberg, Heidelberg, Germany; Christos Dervenis, the Agia Olga Hospital, Athens, Greece; Attila Oláh, the Petz Aladar Hospital, Gyor, Hungary; Pehr A. Lind, Karolinska-Stockholm Söder Hospital, Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Palmer, Daniel" sort="Palmer, Daniel" uniqKey="Palmer D" first="Daniel" last="Palmer">Daniel Palmer</name></author><author><name sortKey="Jackson, Richard" sort="Jackson, Richard" uniqKey="Jackson R" first="Richard" last="Jackson">Richard Jackson</name></author><author><name sortKey="Cox, Trevor" sort="Cox, Trevor" uniqKey="Cox T" first="Trevor" last="Cox">Trevor Cox</name></author><author><name sortKey="Neoptolemos, John P" sort="Neoptolemos, John P" uniqKey="Neoptolemos J" first="John P" last="Neoptolemos">John P. Neoptolemos</name></author><author><name sortKey="Ghaneh, Paula" sort="Ghaneh, Paula" uniqKey="Ghaneh P" first="Paula" last="Ghaneh">Paula Ghaneh</name></author><author><name sortKey="Rawcliffe, Charlotte L" sort="Rawcliffe, Charlotte L" uniqKey="Rawcliffe C" first="Charlotte L" last="Rawcliffe">Charlotte L. Rawcliffe</name></author><author><name sortKey="Bassi, Claudio" sort="Bassi, Claudio" uniqKey="Bassi C" first="Claudio" last="Bassi">Claudio Bassi</name></author><author><name sortKey="Stocken, Deborah D" sort="Stocken, Deborah D" uniqKey="Stocken D" first="Deborah D" last="Stocken">Deborah D. Stocken</name></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name></author><author><name sortKey="O Reilly, Derek" sort="O Reilly, Derek" uniqKey="O Reilly D" first="Derek" last="O'Reilly">Derek O'Reilly</name></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name></author><author><name sortKey="Robinson, Bridget A" sort="Robinson, Bridget A" uniqKey="Robinson B" first="Bridget A" last="Robinson">Bridget A. Robinson</name></author><author><name sortKey="Karapetis, Christos" sort="Karapetis, Christos" uniqKey="Karapetis C" first="Christos" last="Karapetis">Christos Karapetis</name></author><author><name sortKey="Scarfe, Andrew" sort="Scarfe, Andrew" uniqKey="Scarfe A" first="Andrew" last="Scarfe">Andrew Scarfe</name></author><author><name sortKey="Lacaine, Francois" sort="Lacaine, Francois" uniqKey="Lacaine F" first="Francois" last="Lacaine">Francois Lacaine</name></author><author><name sortKey="Sand, Juhani" sort="Sand, Juhani" uniqKey="Sand J" first="Juhani" last="Sand">Juhani Sand</name></author><author><name sortKey="Izbicki, Jakob R" sort="Izbicki, Jakob R" uniqKey="Izbicki J" first="Jakob R" last="Izbicki">Jakob R. Izbicki</name></author><author><name sortKey="Mayerle, Julia" sort="Mayerle, Julia" uniqKey="Mayerle J" first="Julia" last="Mayerle">Julia Mayerle</name></author><author><name sortKey="Dervenis, Christos" sort="Dervenis, Christos" uniqKey="Dervenis C" first="Christos" last="Dervenis">Christos Dervenis</name></author><author><name sortKey="Olah, Attila" sort="Olah, Attila" uniqKey="Olah A" first="Attila" last="Oláh">Attila Oláh</name></author><author><name sortKey="Butturini, Giovanni" sort="Butturini, Giovanni" uniqKey="Butturini G" first="Giovanni" last="Butturini">Giovanni Butturini</name></author><author><name sortKey="Lind, Pehr A" sort="Lind, Pehr A" uniqKey="Lind P" first="Pehr A" last="Lind">Pehr A. Lind</name></author><author><name sortKey="Middleton, Mark R" sort="Middleton, Mark R" uniqKey="Middleton M" first="Mark R" last="Middleton">Mark R. Middleton</name></author><author><name sortKey="Anthoney, Alan" sort="Anthoney, Alan" uniqKey="Anthoney A" first="Alan" last="Anthoney">Alan Anthoney</name></author><author><name sortKey="Sumpter, Kate" sort="Sumpter, Kate" uniqKey="Sumpter K" first="Kate" last="Sumpter">Kate Sumpter</name></author><author><name sortKey="Carter, Ross" sort="Carter, Ross" uniqKey="Carter R" first="Ross" last="Carter">Ross Carter</name></author><author><name sortKey="Buchler, Markus W" sort="Buchler, Markus W" uniqKey="Buchler M" first="Markus W" last="Büchler">Markus W. Büchler</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24419109</idno><idno type="pmid">24419109</idno><idno type="doi">10.1200/JCO.2013.50.7657</idno><idno type="wicri:Area/PubMed/Corpus">003966</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003966</idno><idno type="wicri:Area/PubMed/Curation">003851</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003851</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.</title><author><name sortKey="Valle, Juan W" sort="Valle, Juan W" uniqKey="Valle J" first="Juan W" last="Valle">Juan W. Valle</name><affiliation wicri:level="1"><nlm:affiliation>Juan W. Valle, Derek O'Reilly, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester; Richard Jackson, Trevor Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte L. Rawcliffe, Liverpool Cancer Research UK Centre and the National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, Liverpool; Daniel Palmer, the Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust; Deborah D. Stocken, the Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; David Cunningham, Royal Marsden Hospital Foundation Trust, Sutton; Mark R. Middleton, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford; Alan Anthoney, The Leeds Teaching Hospital Trust, Leeds; Kate Sumpter, Freeman Hospital, Newcastle upon Tyne; Ross Carter, Glasgow Royal Infirmary, Glasgow, United Kingdom; Claudio Bassi, Giovanni Butturini, University of Verona, Verona, Italy; David Goldstein, Bridget A. Robinson, Christos Karapetis, the Australasian Gastro-Intestinal Trials Group, Camperdown, Australia; Andrew Scarfe, University of Alberta, Edmonton, Canada; Francois Lacaine, Hôpital TENON, Assistance Publique Hôpitaux de Paris, Universite Pierre Et Marie Curie, Paris, France; Juhani Sand, Tampere University Hospital, Tampere, Finland; Jakob R. Izbicki, University of Hamburg, Hamburg; Julia Mayerle, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald; Markus W. Büchler, University of Heidelberg, Heidelberg, Germany; Christos Dervenis, the Agia Olga Hospital, Athens, Greece; Attila Oláh, the Petz Aladar Hospital, Gyor, Hungary; Pehr A. Lind, Karolinska-Stockholm Söder Hospital, Stockholm, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Juan W. Valle, Derek O'Reilly, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester; Richard Jackson, Trevor Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte L. Rawcliffe, Liverpool Cancer Research UK Centre and the National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, Liverpool; Daniel Palmer, the Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust; Deborah D. Stocken, the Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; David Cunningham, Royal Marsden Hospital Foundation Trust, Sutton; Mark R. Middleton, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford; Alan Anthoney, The Leeds Teaching Hospital Trust, Leeds; Kate Sumpter, Freeman Hospital, Newcastle upon Tyne; Ross Carter, Glasgow Royal Infirmary, Glasgow, United Kingdom; Claudio Bassi, Giovanni Butturini, University of Verona, Verona, Italy; David Goldstein, Bridget A. Robinson, Christos Karapetis, the Australasian Gastro-Intestinal Trials Group, Camperdown, Australia; Andrew Scarfe, University of Alberta, Edmonton, Canada; Francois Lacaine, Hôpital TENON, Assistance Publique Hôpitaux de Paris, Universite Pierre Et Marie Curie, Paris, France; Juhani Sand, Tampere University Hospital, Tampere, Finland; Jakob R. Izbicki, University of Hamburg, Hamburg; Julia Mayerle, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald; Markus W. Büchler, University of Heidelberg, Heidelberg, Germany; Christos Dervenis, the Agia Olga Hospital, Athens, Greece; Attila Oláh, the Petz Aladar Hospital, Gyor, Hungary; Pehr A. Lind, Karolinska-Stockholm Söder Hospital, Stockholm</wicri:regionArea></affiliation></author><author><name sortKey="Palmer, Daniel" sort="Palmer, Daniel" uniqKey="Palmer D" first="Daniel" last="Palmer">Daniel Palmer</name></author><author><name sortKey="Jackson, Richard" sort="Jackson, Richard" uniqKey="Jackson R" first="Richard" last="Jackson">Richard Jackson</name></author><author><name sortKey="Cox, Trevor" sort="Cox, Trevor" uniqKey="Cox T" first="Trevor" last="Cox">Trevor Cox</name></author><author><name sortKey="Neoptolemos, John P" sort="Neoptolemos, John P" uniqKey="Neoptolemos J" first="John P" last="Neoptolemos">John P. Neoptolemos</name></author><author><name sortKey="Ghaneh, Paula" sort="Ghaneh, Paula" uniqKey="Ghaneh P" first="Paula" last="Ghaneh">Paula Ghaneh</name></author><author><name sortKey="Rawcliffe, Charlotte L" sort="Rawcliffe, Charlotte L" uniqKey="Rawcliffe C" first="Charlotte L" last="Rawcliffe">Charlotte L. Rawcliffe</name></author><author><name sortKey="Bassi, Claudio" sort="Bassi, Claudio" uniqKey="Bassi C" first="Claudio" last="Bassi">Claudio Bassi</name></author><author><name sortKey="Stocken, Deborah D" sort="Stocken, Deborah D" uniqKey="Stocken D" first="Deborah D" last="Stocken">Deborah D. Stocken</name></author><author><name sortKey="Cunningham, David" sort="Cunningham, David" uniqKey="Cunningham D" first="David" last="Cunningham">David Cunningham</name></author><author><name sortKey="O Reilly, Derek" sort="O Reilly, Derek" uniqKey="O Reilly D" first="Derek" last="O'Reilly">Derek O'Reilly</name></author><author><name sortKey="Goldstein, David" sort="Goldstein, David" uniqKey="Goldstein D" first="David" last="Goldstein">David Goldstein</name></author><author><name sortKey="Robinson, Bridget A" sort="Robinson, Bridget A" uniqKey="Robinson B" first="Bridget A" last="Robinson">Bridget A. Robinson</name></author><author><name sortKey="Karapetis, Christos" sort="Karapetis, Christos" uniqKey="Karapetis C" first="Christos" last="Karapetis">Christos Karapetis</name></author><author><name sortKey="Scarfe, Andrew" sort="Scarfe, Andrew" uniqKey="Scarfe A" first="Andrew" last="Scarfe">Andrew Scarfe</name></author><author><name sortKey="Lacaine, Francois" sort="Lacaine, Francois" uniqKey="Lacaine F" first="Francois" last="Lacaine">Francois Lacaine</name></author><author><name sortKey="Sand, Juhani" sort="Sand, Juhani" uniqKey="Sand J" first="Juhani" last="Sand">Juhani Sand</name></author><author><name sortKey="Izbicki, Jakob R" sort="Izbicki, Jakob R" uniqKey="Izbicki J" first="Jakob R" last="Izbicki">Jakob R. Izbicki</name></author><author><name sortKey="Mayerle, Julia" sort="Mayerle, Julia" uniqKey="Mayerle J" first="Julia" last="Mayerle">Julia Mayerle</name></author><author><name sortKey="Dervenis, Christos" sort="Dervenis, Christos" uniqKey="Dervenis C" first="Christos" last="Dervenis">Christos Dervenis</name></author><author><name sortKey="Olah, Attila" sort="Olah, Attila" uniqKey="Olah A" first="Attila" last="Oláh">Attila Oláh</name></author><author><name sortKey="Butturini, Giovanni" sort="Butturini, Giovanni" uniqKey="Butturini G" first="Giovanni" last="Butturini">Giovanni Butturini</name></author><author><name sortKey="Lind, Pehr A" sort="Lind, Pehr A" uniqKey="Lind P" first="Pehr A" last="Lind">Pehr A. Lind</name></author><author><name sortKey="Middleton, Mark R" sort="Middleton, Mark R" uniqKey="Middleton M" first="Mark R" last="Middleton">Mark R. Middleton</name></author><author><name sortKey="Anthoney, Alan" sort="Anthoney, Alan" uniqKey="Anthoney A" first="Alan" last="Anthoney">Alan Anthoney</name></author><author><name sortKey="Sumpter, Kate" sort="Sumpter, Kate" uniqKey="Sumpter K" first="Kate" last="Sumpter">Kate Sumpter</name></author><author><name sortKey="Carter, Ross" sort="Carter, Ross" uniqKey="Carter R" first="Ross" last="Carter">Ross Carter</name></author><author><name sortKey="Buchler, Markus W" sort="Buchler, Markus W" uniqKey="Buchler M" first="Markus W" last="Büchler">Markus W. Büchler</name></author></analytic><series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title><idno type="eISSN">1527-7755</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenocarcinoma (drug therapy)</term><term>Adenocarcinoma (surgery)</term><term>Aged</term><term>Antimetabolites, Antineoplastic (administration & dosage)</term><term>Carcinoma, Pancreatic Ductal (drug therapy)</term><term>Carcinoma, Pancreatic Ductal (surgery)</term><term>Chemotherapy, Adjuvant (methods)</term><term>Deoxycytidine (administration & dosage)</term><term>Deoxycytidine (analogs & derivatives)</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Fluorouracil (administration & dosage)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pancreatic Neoplasms (drug therapy)</term><term>Pancreatic Neoplasms (surgery)</term><term>Survival Analysis</term><term>Survival Rate</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénocarcinome ()</term><term>Adénocarcinome (traitement médicamenteux)</term><term>Analyse de survie</term><term>Antinéoplasiques antimétabolites (administration et posologie)</term><term>Calendrier d'administration des médicaments</term><term>Carcinome du canal pancréatique ()</term><term>Carcinome du canal pancréatique (traitement médicamenteux)</term><term>Désoxycytidine (administration et posologie)</term><term>Désoxycytidine (analogues et dérivés)</term><term>Femelle</term><term>Fluorouracil (administration et posologie)</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Traitement médicamenteux adjuvant ()</term><term>Tumeurs du pancréas ()</term><term>Tumeurs du pancréas (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antimetabolites, Antineoplastic</term><term>Deoxycytidine</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Deoxycytidine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antinéoplasiques antimétabolites</term><term>Désoxycytidine</term><term>Fluorouracil</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Désoxycytidine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Adenocarcinoma</term><term>Carcinoma, Pancreatic Ductal</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Adenocarcinoma</term><term>Carcinoma, Pancreatic Ductal</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Adénocarcinome</term><term>Carcinome du canal pancréatique</term><term>Tumeurs du pancréas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disease-Free Survival</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Survival Analysis</term><term>Survival Rate</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Adénocarcinome</term><term>Analyse de survie</term><term>Calendrier d'administration des médicaments</term><term>Carcinome du canal pancréatique</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Sujet âgé</term><term>Survie sans rechute</term><term>Taux de survie</term><term>Traitement médicamenteux adjuvant</term><term>Tumeurs du pancréas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24419109</PMID><DateCreated><Year>2014</Year><Month>02</Month><Day>17</Day></DateCreated><DateCompleted><Year>2014</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>20</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.</ArticleTitle><Pagination><MedlinePgn>504-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2013.50.7657</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Adjuvant chemotherapy improves patient survival rates after resection for pancreatic adenocarcinoma, but the optimal duration and time to initiate chemotherapy is unknown.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with pancreatic ductal adenocarcinoma treated within the international, phase III, European Study Group for Pancreatic Cancer-3 (version 2) study were included if they had been randomly assigned to chemotherapy. Overall survival analysis was performed on an intention-to-treat basis, retaining patients in their randomized groups, and adjusting the overall treatment effect by known prognostic variables as well as the start time of chemotherapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There were 985 patients, of whom 486 (49%) received gemcitabine and 499 (51%) received fluorouracil; 675 patients (68%) completed all six cycles of chemotherapy (full course) and 293 patients (30%) completed one to five cycles. Lymph node involvement, resection margins status, tumor differentiation, and completion of therapy were all shown by multivariable Cox regression to be independent survival factors. Overall survival favored patients who completed the full six courses of treatment versus those who did not (hazard ratio [HR], 0.516; 95% CI, 0.443 to 0.601; P < .001). Time to starting chemotherapy did not influence overall survival rates for the full study population (HR, 0.985; 95% CI, 0.956 to 1.015). Chemotherapy start time was an important survival factor only for the subgroup of patients who did not complete therapy, in favor of later treatment (P < .001).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Completion of all six cycles of planned adjuvant chemotherapy rather than early initiation was an independent prognostic factor after resection for pancreatic adenocarcinoma. There seems to be no difference in outcome if chemotherapy is delayed up to 12 weeks, thus allowing adequate time for postoperative recovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Juan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Juan W. Valle, Derek O'Reilly, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust and University of Manchester, Manchester; Richard Jackson, Trevor Cox, John P. Neoptolemos, Paula Ghaneh, Charlotte L. Rawcliffe, Liverpool Cancer Research UK Centre and the National Institute for Health Research Pancreas Biomedical Research Unit, University of Liverpool, Liverpool; Daniel Palmer, the Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust; Deborah D. Stocken, the Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham; David Cunningham, Royal Marsden Hospital Foundation Trust, Sutton; Mark R. Middleton, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford; Alan Anthoney, The Leeds Teaching Hospital Trust, Leeds; Kate Sumpter, Freeman Hospital, Newcastle upon Tyne; Ross Carter, Glasgow Royal Infirmary, Glasgow, United Kingdom; Claudio Bassi, Giovanni Butturini, University of Verona, Verona, Italy; David Goldstein, Bridget A. Robinson, Christos Karapetis, the Australasian Gastro-Intestinal Trials Group, Camperdown, Australia; Andrew Scarfe, University of Alberta, Edmonton, Canada; Francois Lacaine, Hôpital TENON, Assistance Publique Hôpitaux de Paris, Universite Pierre Et Marie Curie, Paris, France; Juhani Sand, Tampere University Hospital, Tampere, Finland; Jakob R. Izbicki, University of Hamburg, Hamburg; Julia Mayerle, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald; Markus W. Büchler, University of Heidelberg, Heidelberg, Germany; Christos Dervenis, the Agia Olga Hospital, Athens, Greece; Attila Oláh, the Petz Aladar Hospital, Gyor, Hungary; Pehr A. Lind, Karolinska-Stockholm Söder Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palmer</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Trevor</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Neoptolemos</LastName><ForeName>John P</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Ghaneh</LastName><ForeName>Paula</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Rawcliffe</LastName><ForeName>Charlotte L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Bassi</LastName><ForeName>Claudio</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stocken</LastName><ForeName>Deborah D</ForeName><Initials>DD</Initials></Author><Author ValidYN="Y"><LastName>Cunningham</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Derek</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Goldstein</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Bridget A</ForeName><Initials>BA</Initials></Author><Author ValidYN="Y"><LastName>Karapetis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Scarfe</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Lacaine</LastName><ForeName>Francois</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sand</LastName><ForeName>Juhani</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Izbicki</LastName><ForeName>Jakob R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Mayerle</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dervenis</LastName><ForeName>Christos</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Oláh</LastName><ForeName>Attila</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Butturini</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Lind</LastName><ForeName>Pehr A</ForeName><Initials>PA</Initials></Author><Author ValidYN="Y"><LastName>Middleton</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Anthoney</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sumpter</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Ross</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Büchler</LastName><ForeName>Markus W</ForeName><Initials>MW</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN37494643</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000964">Antimetabolites, Antineoplastic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0W860991D6</RegistryNumber><NameOfSubstance UI="D003841">Deoxycytidine</NameOfSubstance></Chemical><Chemical><RegistryNumber>B76N6SBZ8R</RegistryNumber><NameOfSubstance UI="C056507">gemcitabine</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3P01618RT</RegistryNumber><NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2014 Feb 20;32(6):487-8</RefSource><PMID Version="1">24419124</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Chirurg. 2014 Jun;85(6):543</RefSource><PMID Version="1">24824005</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="N">Adenocarcinoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000964" MajorTopicYN="N">Antimetabolites, Antineoplastic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021441" MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003841" MajorTopicYN="N">Deoxycytidine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005472" MajorTopicYN="N">Fluorouracil</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010190" MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24419109</ArticleId><ArticleId IdType="pii">JCO.2013.50.7657</ArticleId><ArticleId IdType="doi">10.1200/JCO.2013.50.7657</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003851 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003851 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:24419109
|texte= Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:24419109" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |